search

Active clinical trials for "Epidermolysis Bullosa"

Results 101-110 of 120

A Follow-up Study to Evaluate the Efficacy and Safety of ALLO-ASC-DFU in ALLO-ASC-EB-101 Clinical...

Dystrophic Epidermolysis Bullosa

This is an open-label follow up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 1/2 clinical trial(ALLO-ASC-EB-101) for 24 months.

Completed3 enrollment criteria

Study of Inflammatory Mechanisms in Epidermolysis Bullosa Simplex- Dowling Meara

Epidermolysis Bullosa Simplex Dowling Meara

Introduction: Epidermolysis Bullosa Simplex-Dowling-Meara (DM-EBS) is a rare genodermatosis characterized by spontaneous or post traumatic large cutaneous blisters. No curative treatment is actually available. Some data suggest a role of inflammation in the occurrence of blisters. The aim of this study is to study the epidermis inflammatory mechanisms in DM-EBS. Material and methods: A first retrospective immunohistochemical study will be led on remainder skin biopsies of DM-EBS patients took for the diagnosis. A second clinical multicentric prospective study will be led on 8 patients older than 1 year with severe DM-EBS. After informed written consent, they will answer to a standardized questionnaire. In case of flare of the disease, the liquid and the top of the blisters will be took. Samples will be analyzed in the Pr Nicolas 851 INSERM unit. After centrifugation of the liquid blisters, the repartition of inflammatory cells will be evaluated by Fluorescence Activated Cell Sorting on the pellet. Markers of inflammation will be evaluated on the surnageant with Luminex® technical with a multiplex targeting cytokines and chemokines. An immuno-histochemic analysis in association with a quantitative PCR will be made on the top of the blisters. If unknown, genotypic study will be made. Perspectives: A better comprehension of physiopathological mechanisms in DM-EBS could offer new therapeutic ways.

Completed12 enrollment criteria

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis...

Epidermolysis Bullosa (EB)Epidermolysis Bullosa Simplex2 more

A pharmacokinetic (PK) study in 16-20 EB subjects to be allocated to two cohorts. Cohort 1 to include 8-10 subjects (ages 12 yrs and older); Cohort 2 to include 8-10 subjects (ages 6 months-11 yrs, inclusive). Cohort 2 only included subjects 4 yrs and older. Serial PK blood sampling collected on Days 1 and 10. Analyses were performed to determine the concentrations of diacerein and rhein.

Completed11 enrollment criteria

Short Term Observational Study in DEB Patients

Dystrophic Epidermolysis Bullosa

The purpose of this study is to better understand disease extent and to identify appropriate methodologies to evaluate (dystrophic epidermolysis bullosa) DEB in a quantitative and qualitative manner.

Completed7 enrollment criteria

Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer

Epidermolysis Bullosa Dystrophica

Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a severe inherited blistering skin disease caused by absence of type VII collagen. Patients with RDEB develop large, severly painful blisters and open wounds from minor trauma to their skin. In the future, we hope to start a gene transfer study on a specific group of RDEB subjects and we are screening subjects for that potential trial now.

Terminated0 enrollment criteria

Mesenchymal Stromal Cells in Adults With Recessive Dystrophic Epidermolysis Bullosa

Recessive Dystrophic Epidermolysis Bullosa

To assess whether intravenously administered third-party bone marrow-derived mesenchymal stromal cells (MSCs) are safe and have an impact on disease severity in RDEB

Unknown status8 enrollment criteria

The Natural History of Wounds in Patients With Dystrophic Epidermolysis Bullosa (DEB)

Dystrophic Epidermolysis BullosaDEB - Dystrophic Epidermolysis Bullosa

This study is a non-interventional, observational study that will evaluate the natural history of wounds in patients with Dystrophic Epidermolysis Bullosa (DEB) for inclusion into the Krystal Biotech Phase III protocol of B-VEC (previously KB103). Wound recurrence and wound size will be evaluated for up to four months.

Withdrawn6 enrollment criteria

Survey to Identify Burdens and Unmet Needs of Patients With Epidermolysis Bullosa

Epidermolysis Bullosa

This survey intends to collect information on key aspects of life with epidermolysis bullosa (EB), including diagnostic journey, treatment, management, daily living challenges, and overall psycho-social, socio-economic, academic and family impact. Objectives: To understand the unmet needs for people living with EB in the US To assess the differences/similarities in the management/treatment of EB patients (including wound care, symptom management and other issues) To assess the EB patients' and caregivers' perceptions of current management/treatment To assess the challenges and the burden of daily living with EB To understand EB diagnostic journey (the time to diagnosis and by what type of healthcare provider) To identify professional disciplines involved in the diagnosis and management of EB To understand the psycho-social, socio-economic, academic, and family impact of EB

Completed7 enrollment criteria

Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa

Epidermolysis Bullosa Dystrophica

Recessive dystrophic epidermolysis bullosa (RDEB) is a severe inherited blistering disease caused by the absence of type VII collagen. Patients with RDEB develop large, severely painful blisters and open wounds from minor trauma to their skin. We are screening RDEB subjects to determine additional characteristics of patients who survive to adulthood.

Completed0 enrollment criteria

Establishment of the National Epidermolysis Bullosa Registry

Epidermolysis Bullosa

OBJECTIVES: I. Develop a large roster of well-characterized patients with various forms of inherited and acquired epidermolysis bullosa (EB). II. Generate a large data bank of clinical, historical, and genetic information concerning these patients. III. Accumulate donated tissue specimens, including selected cells and DNA, from selected patient subsets for the establishment of permanent tissue cell banks. IV. Promote and facilitate research in EB.

Completed1 enrollment criteria
1...101112

Need Help? Contact our team!


We'll reach out to this number within 24 hrs